FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
HEIDELBERG, Germany, May 23, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Annual General Meeting of Shareholders will be held on Tuesday, June 21, 2016. The meeting will be held at Hilton Amsterdam, Apollolaan 138, 1077 BG Amsterdam, The Netherlands. The meeting will start at 3:00 p.m. CET.
The notice and agenda of the general meeting are available free of charge in the Investor Relations section under "Notice to convene the Annual General Meeting of Shareholders of Affimed N.V." of Affimed's corporate website at www.affimed.com. They are also available on the SEC's website at www.sec.gov.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
